This supports the notion that although CRP remains a valuable inflammatory biomarker in DCM, it may be inadequate to capture the full clinical heterogeneity when used alone, and that a multi-biomarker approach may partially compensate for this limitation. This evidence concerns the gene CRP and familial dilated cardiomyopathy.